The NHS has announced a new clinical commissioning policy for combination brentuximab vedotin and bendamustine for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma, marking another recent development in cancer care in England. The policy was published on 16 July 2026 and adds to a busy week for NHS cancer news, including figures showing that cancer patients continue to rate their care highly while record numbers are being checked and treated.
A targeted option for difficult-to-treat blood cancer
The policy covers patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma, offering a new treatment route for a group with limited options after standard therapy. The document was released through NHS England on 16 July 2026 and is the latest in a sequence of cancer-related announcements from the service this month. NHS England policy
The move follows a wider pattern of recent NHS action on cancer medicines. In early June, the health service said hundreds of women with hard-to-treat ovarian cancer could benefit from a new life-extending drug, and later in June it announced another immunotherapy for women with aggressive cervical cancer. Together, these decisions show how the NHS continues to expand access to specialist treatments through its cancer commissioning framework.
Record activity and strong patient feedback
The latest NHS cancer update also highlighted that tens of thousands of cancer patients have rated the care they received as nearly 9 out of 10, while NHS teams have seen and treated record numbers of people for the disease. The same update said NHS cancer checks have reached nearly 3.4 million in a year, more than doubling over the last decade. NHS England news
That combination of high demand and positive patient feedback suggests the service is continuing to handle large volumes of cancer care while introducing additional treatment options. The timing is notable, coming just days after NHS England urged people in their 50s to return bowel screening kits after 100 cancers were found a week, underlining the importance of screening and earlier diagnosis in the NHS cancer strategy.
What the latest policy means for patients
For families affected by classical Hodgkin lymphoma, the policy may offer another route when first-line treatment has not worked or the disease has returned. While the NHS release does not provide detailed patient numbers in the summary available, the policy’s age range suggests it is intended for both children and adults. The announcement fits into a broader July trend in which the NHS has focused on cancer detection, access to treatment and service performance.
With more cancer patients being checked and treated, and with new drug access continuing to expand, the NHS is signalling that cancer care remains one of its most active clinical priorities. The latest commissioning decision adds to that momentum and gives clinicians another option to consider in a difficult-to-treat blood cancer pathway.
